Strong acceleration of e-Rx sales in Germany for Redcare Pharmacy, from 7%
growth in Q1 to 37% in Q2.

EQS-News: Redcare Pharmacy N.V. / Key word(s): Preliminary
Results/Development of Sales
Strong acceleration of e-Rx sales in Germany for Redcare Pharmacy, from 7%
growth in Q1 to 37% in Q2.

04.07.2024 / 06:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Strong acceleration of e-Rx sales in Germany for Redcare Pharmacy, from 7%
growth in Q1 to 37% in Q2.

* Total sales reached EUR 560M in Q2, up 33% year over year.

  * Non-Rx sales totaled EUR 390M, steady continuation of fast growth, up
    21% year over year.

  * Rx sales increased to EUR 50M in Germany, 37% growth in Q2 year over
    year, while CardLink was launched on 6 May.

  * Active customer base expanded to 11.6M, up 0.4M in Q2 and 1.4M in one
    year.

Sevenum, the Netherlands, 4 July 2024. Today, Redcare Pharmacy N.V. released
preliminary and unaudited sales numbers for the second quarter. Unabated,
double-digit growth in sales and the active customer base continued for the
Group. The fully digital e-Rx redemption method via the health card
(CardLink) was launched on 6 May. First results showed a rapid increase in
prescription sales, with the quarter average Rx growth accelerating from
6.8% in Q1 to 36.6% in Q2 in Germany. Redcare Pharmacy´s total Group sales
increased 33.3% to EUR 560 million (Q2 2023: EUR 420 million), bringing
year-to-date sales to EUR 1,120 million and growth to 41.4% (H1 2023: EUR
792 million).

Redcare Pharmacy's CEO, Olaf Heinrich comments: "Finally, we can offer
patients across Germany a fully digital journey to get their prescription
drugs easily, safely and quickly. Following the nationwide adoption of e-Rx
and the successful launch of CardLink, we have received very positive
feedback from both existing and new customers. We see our reliable and
patient-friendly, digital journey as a significant addition to the total
healthcare system improving the lives of millions."

Non-Rx sales for the Group grew 20.7% to EUR 390 million in Q2, bringing
year-to-date growth to 20.3% and sales to EUR 795 million. Total Rx sales
were EUR 170 million in Q2 and EUR 325 million year to date. Excluding
MediService, which has been consolidated since mid-May last year, Redcare
Pharmacy's growth was 22.3% in Q2 and 20.4% year to date.

The active customer base expanded to 11.6 million, up 1.4 million over the
past year and 0.4 million in Q2. The NPS (customer net promoter score)
remained at a high level of 68.

CFO Jasper Eenhorst adds: "As the acceleration in Q2's Rx sales shows, we
are focused on the vast e-Rx opportunity in Germany, where we are benefiting
from our strong brand and services. In parallel, we see continued strength
in our OTC and BPC performance both in Germany and in Europe. We increased
marketing in e-Rx, still we feel comfortable that the margin in Q2 will be
within the full-year guidance range of 2% to 4%."

Sales in the DACH segment (Germany, Austria and Switzerland) increased 35.3%
in Q2 to EUR 452 million (Q2 2023: EUR 334 million). Excluding MediService,
sales in DACH grew 21.4%. Non-Rx sales growth was 19.1% to EUR 283 million
(Q2 2023: EUR 237 million). Prescription medication sales (Rx) rose by 75.2%
to EUR 170 million. Excluding MediService, Rx sales growth accelerated from
6.8% in Q1 to 36.6% in Q2.

In the International segment (Belgium, Italy, France, and the Netherlands)
sales also continued to grow at a fast rate of 25.1% to EUR 107 million (Q2
2023: EUR 86 million).

All published figures are preliminary and unaudited. Redcare Pharmacy N.V.
will release the full interim report for H1 2024 on 30 July 2024.

Investor Relations Contact:

Monica Ambrosi (Associate Director, Investor Relations)

investors@redcare-pharmacy.com

Press Contact:

Sven Schirmer (Director, Corporate Communications)

press@redcare-pharmacy.com


About Redcare Pharmacy.

Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop
Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently
active in seven countries: Germany, Austria, France, Belgium, Italy, the
Netherlands and Switzerland.

Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart
of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren,
Warsaw, Milan, Lille and Eindhoven.

As the one-stop pharmacy of the future, Redcare Pharmacy offers over 11
million active customers a wide range of more than 150,000 products at
attractive and fair prices. Besides OTC, nutritional supplements, beauty and
personal care products (BPC) as well as an extensive assortment of
health-related products in all markets, the company also provides
prescription drugs for customers in Germany, Switzerland and the
Netherlands.

Pharmaceutical safety is of top priority. Being a pharmacy at its core,
Redcare stands for comprehensive pharmaceutical consultation service. Since
care is at the heart of everything Redcare does, the company provides
services for all stages of life and health. This ranges from its
marketplaces to unique delivery options and medication management.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the
Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023,
the company is a member of the MDAX selection index.


---------------------------------------------------------------------------

04.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Redcare Pharmacy N.V.
                   Erik de Rodeweg 11-13
                   5975 WD Sevenum
                   Netherlands
   Phone:          0800 - 200 800 300
   Fax:            0800 - 90 70 90 20
   E-mail:         investors@redcare-pharmacy.com
   Internet:       www.redcare-pharmacy.com
   ISIN:           NL0012044747, DE000A19Y072
   WKN:            A2AR94, A19Y072
   Indices:        MDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1939317

End of News EQS News Service
---------------------------------------------------------------------------

1939317 04.07.2024 CET/CEST